|
Market Closed -
Nasdaq
16:00:00 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 2.800 USD | +6.87% |
|
+6.87% | +71.78% |
| 08-13 | Ovid Therapeutics Reports Pipeline and Business Updates | CI |
| 08-13 | Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Ovid Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 218.6 | 131.1 | 227.6 | 66.3 | 212.2 | 489 | - | - |
| Change | - | -40.04% | 73.64% | -70.87% | 220.05% | 130.44% | - | - |
| Enterprise Value (EV) | 218.6 | 131.1 | 227.6 | 66.3 | 212.2 | 489 | 489 | 489 |
| Change | - | -40.04% | 73.64% | -70.87% | 220.05% | 130.44% | 0% | 0% |
| P/E | 1.82x | -2.42x | -4.35x | -2.52x | -7.09x | -7.08x | -5.17x | -4.25x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 1.12x | 0.1x | 0.2x | -0.1x | -0.1x | -0.2x |
| Capitalization / Revenue | 1.05x | 87.2x | 581x | 117x | 29.3x | 3,639x | 2,282x | 2,551x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3,639x | 2,282x | 2,551x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -6.92x | -5.44x | -4.24x |
| EV / FCF | - | - | - | - | -0x | -6.59x | -5.73x | -4.95x |
| FCF Yield | - | - | - | - | -18.1% | -15.2% | -17.5% | -20.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.76 | -0.77 | -0.74 | -0.37 | -0.23 | -0.37 | -0.5067 | -0.6167 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 208.4 | 1.503 | 0.3917 | 0.566 | 7.252 | 0.1344 | 0.2143 | 0.1917 |
| EBITDA | 124.4 | -55.04 | -57.68 | -60.18 | - | - | - | - |
| EBIT 1 | 149.2 | -55.55 | -59.28 | -61.88 | -42.44 | -70.71 | -89.83 | -115.3 |
| Net income 1 | 122.8 | -54.17 | -52.34 | -26.43 | -17.41 | -67.33 | -89.03 | -114.9 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 3.210 | 1.860 | 3.220 | 0.934 | 1.630 | 2.620 | 2.620 | 2.620 |
| Nbr of stocks (in thousands) | 68,092 | 70,467 | 70,681 | 71,010 | 130,184 | 186,640 | - | - |
| Announcement Date | 3/15/22 | 3/13/23 | 3/8/24 | 3/11/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.42x | - | - | - | 489M | |
| 20.94x | 7.34x | 14.96x | 1.38% | 70.1B | |
| 31.3x | 7.97x | 24.33x | 0.05% | 54.93B | |
| -86.53x | 15.66x | -79.82x | -.--% | 28.89B | |
| 30.32x | 5.94x | 15.72x | -.--% | 23.9B | |
| -14.59x | 5.14x | -6.7x | -.--% | 23.3B | |
| 55.29x | 22.62x | 58.25x | 0.07% | 18.41B | |
| 25.72x | 4.87x | 16.34x | -.--% | 18.77B | |
| -1224.8x | 38.27x | -15166.74x | -.--% | 16.1B | |
| 15.63x | 4.6x | 10.74x | -.--% | 12.48B | |
| Average | -115.21x | 12.49x | -1,679.21x | 0.17% | 26.74B | |
| Weighted average by Cap. | -63.40x | 10.67x | -908.05x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OVID Stock
- Valuation Ovid Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
